Celltrion biosmilar

South Korea's biopharmaceutical company Celltrion Inc. plans to sell all of its biosimilar products through its own sales channels in Europe to impr...

South Korea's biopharmaceutical company Celltrion Inc. and diagnostic kit manufacturer Humasis Co. have signed contracts to supply their jointly-dev...

EcoPro BM Co., a leading manufacturer of cathode material for secondary batteries, topped the market capitalization for Kosdaq-listed firms on Jan...

Biopharmaceutical powerhouse Celltrion Inc. plans to use its treatments to test the Omicron variant detected in Korea, according to a high-level com...

South Korea’s pharmaceutical giant Celltrion Inc. is set to export its COVID-19 treatment Regkirona to Europe by the end of this year as it se...

South Korea’s Celltrion Inc. has long been a biosimilar player, producing replicas of original drugs, a growing market in the pandemic era.Ear...

South Korea’s pharmaceutical giant Celltrion Inc. has won final approval for its COVID-19 treatment Regkirona from the European Commission, a ...

South Korea’s pharmaceutical conglomerate Celltrion Group has made its very first step in reforming corporate governance structure by merging ...

South Korean drugmaker Celltrion Inc. has added Brazil to the list of countries that have granted emergency use approval for its COVID-19 treatment ...

South Korean biosimilar maker Celltrion Inc. will launch the first-phase clinical trials of its new COVID-19 treatment candidate next month, followi...

South Korean drugmaker Celltrion Inc. has received the Indonesian government’s permission for restricted use of its COVID-19 treatment Regkiro...

Celltrion Inc. on July 13 said that its COVID-19 treatment Regkirona has proven effective in reducing the incidence of severe cases of the virus by ...

South Korean biosimilar companies such as Celltrion Inc. and Samsung Bioepis Co. are likely to see their sales hike by tens of millions of dollars...

South Korean biosimilar maker Celltrion Inc. and Mirae Asset Group have agreed to an investment that will render them the top shareholder in Iksuda ...

South Korea-based Celltrion Inc. has alluded to the possibility of developing a COVID-19 vaccine on the grounds that securing a vaccine is essential...

Celltrion Inc. and HLB Inc., two leading South Korean biopharmaceutical shares, shot up on Monday as the main bourse’s key index climbed back ...

South Korea's Celltrion Inc. has completed second-phase clinical trials of its COVID-19 treatment and is seeking conditional approval of its distr...

South Korea's biopharmaceutical firm Celltrion Inc. has completed the $278 million acquisition of Takeda Pharmaceutical Company Ltd's primary care a...

South Korea’s biopharmaceutical firm Celltrion Inc. can unveil an antibody treatment by around the end of the year that is able to kill the COVI...

South Korean biosimilar maker Celltrion Inc's operating profit topped market expectations by more than 20% in the third quarter, hitting a record high...

Seo Jung-jin, founder and chairman of South Korea’s biosimilar maker Celltrion Group, said on Oct. 6 that he is in talks with a number of global...

South Korea’s Celltrion Inc. and its affiliates are expected to post robust operating profits this year on the back of strong sales of Remsima a...

South Korea’s Celltrion Inc. on Sept. 10 rebutted J.P. Morgan’s massive downgrade of its target price for the biopharmaceutical company. T...

Biosimilar maker Celltrion Inc. has agreed to develop a tablet-type treatment for autoimmune diseases jointly with the UK biotech startup Intract Phar...

One Equity Partners (OEP), a New York based private equity firm, unloaded its remaining shares in Celltrion Healthcare valued at approximately 31...